Article
Tampa, Fla. — Among molecularly targeted agents being developed to treat melanoma, some of the most exciting are anti-CTLA-4 antibodies now being developed by Pfizer and Medarex.
The Weekly Roundup: February 10-14
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Daily Derm Times: February 14, 2025
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Nektar's Jonathan Zalevsky, PhD, Dives Into Rezpegaldesleukin Fast Track Designation for Atopic Dermatitis
Tailoring Atopic Dermatitis Treatment to Meet Patient Needs